A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

NCT05380024 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Ensartinib

Sponsor

Peking University Cancer Hospital & Institute